Sarecycline Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 60 mg, 100 mg, 150 mg
Reference Brands: Seysara (USA)
Category:
Derma Drugs
Sarecycline is available in Tablets
and strengths such as 60 mg, 100 mg, 150 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Sarecycline is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Sarecycline can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Sarecycline is a narrow-spectrum, tetracycline-derived antibiotic specifically developed for the treatment of moderate to severe acne vulgaris. Marketed under the brand name Seysara, it was approved by the U.S. FDA in October 2018 for the treatment of inflammatory, non-nodular acne lesions in patients 9 years of age and older. Its approval was supported by two large, randomized, well-controlled clinical trials that evaluated both facial and truncal acne, including lesions on the back and chest, in more than 2,000 patients.
Sarecycline has a unique chemical structure characterized by a long C7 moiety, which allows it to directly interact with bacterial messenger RNA (mRNA). This structural feature contributes to its targeted antibacterial activity. Unlike traditional tetracyclines, Sarecycline exhibits a limited spectrum of action, primarily against Gram-positive bacteria that are clinically relevant in acne, particularly Cutibacterium acnes.
Due to its minimal activity against Gram-negative bacteria commonly found in the gastrointestinal tract, Sarecycline is associated with a lower risk of disrupting normal gut microflora. This targeted profile makes it well suited for long-term acne management, offering effective lesion reduction with improved tolerability compared to broader-spectrum antibiotics.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing